Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

HR: Hazard Ratio; Ca + Vit D: Calcium/vitamin D supplements.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were followed up from T2DM diagnosis until the earliest of death, transfer out, fracture, or end of study.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Fracture risk in type 2 diabetic patients: A clinical prediction tool based on a large population-based cohort

Study design awaiting verification · PLoS ONE · 2018

Original publication title

Fracture risk in type 2 diabetic patients: A clinical prediction tool based on a large population-based cohort

Daniel Martínez-Laguna; Cristian Tebé; Xavier Nogués; M Kassim Javaid; Cyrus Cooper; Victor Moreno; Adolfo Diez-Perez; Gary S. Collins; Daniel Prieto-Alhambra

© 2018 Martínez-Laguna et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The proposed prediction models have good discrimination and calibration for the estimation of both hip and major fracture risk in incident T2DM patients. These tools incorporate key T2DM macrovascular complications generally available in primary care electronic medical records, as well as more generic fracture risk predictors. Future work will focus on validation of these models in external cohorts.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

An increased fracture risk has been described as a complication of Type 2 diabetes mellitus (T2DM). Clinical prediction models for general population have a limited predictive accuracy for fractures in T2DM patients. The aim was to develop and validate a clinical prediction tool for the estimation of 5-year hip and major fracture risk in T2DM patients.

Source: Background

Abstract: Methods and results

A cohort of newly diagnosed T2DM patients (n = 51,143, aged 50 to 85, 57% men) was extracted from the Information System for the Development of Research in Primary Care (SIDIAP) database, containing computerized primary care records for >80% of the population of Catalonia, Spain (>6 million people). Patients were followed up from T2DM diagnosis until the earliest of death, transfer out, fracture, or end of study. Cox proportional hazards regression was used to model the 5-year risk of hip and major fracture.

Calibration and discrimination were assessed. Hip and major fracture incidence rates were 1.84 [95%CI 1.64 to 2.05] and 7.12 [95%CI 6.72 to 7.53] per 1,000 person-years, respectively. Both hip and major fracture prediction models included age, sex, previous major fracture, statins use, and calcium/vitamin D supplements; previous ischemic heart disease was also included for hip fracture and stroke for major fracture. Discrimination (0.81 for hip and 0.72 for major fracture) and calibration plots support excellent internal validity.

Source: Methods and results

Abstract: Conclusions

The proposed prediction models have good discrimination and calibration for the estimation of both hip and major fracture risk in incident T2DM patients. These tools incorporate key T2DM macrovascular complications generally available in primary care electronic medical records, as well as more generic fracture risk predictors. Future work will focus on validation of these models in external cohorts.

Source: Conclusions
Authors’ abstract

Background

An increased fracture risk has been described as a complication of Type 2 diabetes mellitus (T2DM). Clinical prediction models for general population have a limited predictive accuracy for fractures in T2DM patients. The aim was to develop and validate a clinical prediction tool for the estimation of 5-year hip and major fracture risk in T2DM patients.

Methods and results

A cohort of newly diagnosed T2DM patients (n = 51,143, aged 50 to 85, 57% men) was extracted from the Information System for the Development of Research in Primary Care (SIDIAP) database, containing computerized primary care records for >80% of the population of Catalonia, Spain (>6 million people). Patients were followed up from T2DM diagnosis until the earliest of death, transfer out, fracture, or end of study. Cox proportional hazards regression was used to model the 5-year risk of hip and major fracture.

Calibration and discrimination were assessed. Hip and major fracture incidence rates were 1.84 [95%CI 1.64 to 2.05] and 7.12 [95%CI 6.72 to 7.53] per 1,000 person-years, respectively. Both hip and major fracture prediction models included age, sex, previous major fracture, statins use, and calcium/vitamin D supplements; previous ischemic heart disease was also included for hip fracture and stroke for major fracture. Discrimination (0.81 for hip and 0.72 for major fracture) and calibration plots support excellent internal validity.

Conclusions

The proposed prediction models have good discrimination and calibration for the estimation of both hip and major fracture risk in incident T2DM patients. These tools incorporate key T2DM macrovascular complications generally available in primary care electronic medical records, as well as more generic fracture risk predictors. Future work will focus on validation of these models in external cohorts.

Publication and source details

Original title: Fracture risk in type 2 diabetic patients: A clinical prediction tool based on a large population-based cohort

Daniel Martínez-Laguna; Cristian Tebé; Xavier Nogués; M Kassim Javaid; Cyrus Cooper; Victor Moreno; Adolfo Diez-Perez; Gary S. Collins; Daniel Prieto-Alhambra

PLoS ONE · 2018

Competing Interests: We have the following interests: DML has received support from FEIOMM (Bone Research Spanish Foundation) for the submitted work; DML has received personal fees from Eli Lilly, Amgen, and Novartis; CT has received lecture and personal fees from Boehringer Ingelheim; CC has received personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Les Laboratoires Servier, Takeda and UCB; DPA has received grant support from Amgen, Les Laboratoires Servier, and UCB Pharma SRL related to other projects; DPA has previously consulted for UCB Pharma SRL; DPA has received lecture fees from Amgen; XN, MKJ, VM, ADP, and GSC have nothing to declare.

There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: ctebe@idibell.cat
© 2018 Martínez-Laguna et al2018Martínez-Laguna et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.http://dx.doi.org/10.13039/501100000272National Institute for Health ResearchCS-2013-13-012Prieto-Alhambra Daniel Spanish Society for Bone and Mineral ResearchBECAS SEIOMM / FEIOMM 2011This research was partially funded with a grant from the Spanish Society for Bone and Mineral Research (SEIOMM Grants for Clinical Research http://seiomm.org/) (BECAS SEIOMM/FEIOMM 2011) and also by the NIHR Biomedical Research Centre, Oxford. Moreover, DPA is funded by a NIHR Clinician Scientist award (CS-2013-13-012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T21:07:08.107118+00:00

DOI: 10.1371/journal.pone.0203533 · PMC6128577